Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.9800 (2.2%) ($6.8100 - $7.1300) on Wed. Jun. 26, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.3% (three month average) | RSI | 51 | Latest Price | $6.9800(2.2%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.9% a day on average for past five trading days. | Weekly Trend | TGTX declines -0.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) ARKK(57%) IWO(57%) | Factors Impacting TGTX price | TGTX will decline at least -1.65% in a week (0% probabilities). VIXM(-39%) VXX(-38%) TLT(-9%) UUP(-6%) IFRA(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.65% (StdDev 3.3%) | Hourly BBV | 0 () | Intraday Trend | 1% | | | |
|
Resistance Level | $7.08 | 5 Day Moving Average | $7.07(-1.27%) | 10 Day Moving Average | $7.25(-3.72%) | 20 Day Moving Average | $7.08(-1.41%) | To recent high | -17.7% | To recent low | 11.3% | Market Cap | $884m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |